Literature DB >> 2349224

Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy.

R S Bockman1, M A Repo, R P Warrell, J G Pounds, G Schidlovsky, B M Gordon, K W Jones.   

Abstract

Gallium nitrate, a drug that inhibits calcium release from bone, has been proven a safe and effective treatment for the accelerated bone resorption associated with cancer. Though bone is a target organ for gallium, the kinetics, sites, and effects of gallium accumulation in bone are not known. We have used synchrotron x-ray microscopy to map the distribution of trace levels of gallium in bone. After short-term in vivo administration of gallium nitrate to rats, trace (nanogram) amounts of gallium preferentially localized to the metabolically active regions in the metaphysis as well as the endosteal and periosteal surfaces of diaphyseal bone, regions where new bone formation and modeling were occurring. The amounts measured were well below the levels known to be cytotoxic. Iron and zinc, trace elements normally found in bone, were decreased in amount after in vivo administration of gallium. These studies represent a first step toward understanding the mechanism(s) of action of gallium in bone by suggesting the possible cellular, structural, and elemental "targets" of gallium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2349224      PMCID: PMC54065          DOI: 10.1073/pnas.87.11.4149

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Model of aluminum-induced osteomalacia: inhibition of apatite formation and growth.

Authors:  A S Posner; N C Blumenthal; A L Boskey
Journal:  Kidney Int Suppl       Date:  1986-02       Impact factor: 10.545

2.  The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure.

Authors:  E M Clarkson; V A Luck; W V Hynson; R R Bailey; J B Eastwood; J S Woodhead; V R Clements; J L O'Riordan; H E De Wardener
Journal:  Clin Sci       Date:  1972-10       Impact factor: 6.124

3.  Studies on the accumulation mechanisms of radioisotopes used in tumor diagnostic.

Authors:  L J Anghileri
Journal:  Strahlentherapie       Date:  1971-10

4.  In vitro model of aluminum-induced osteomalacia: inhibition of hydroxyapatite formation and growth.

Authors:  N C Blumenthal; A S Posner
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

5.  Bone aluminum and histomorphometric features of renal osteodystrophy.

Authors:  A B Hodsman; D J Sherrard; A C Alfrey; S Ott; A S Brickman; N L Miller; N A Maloney; J W Coburn
Journal:  J Clin Endocrinol Metab       Date:  1982-03       Impact factor: 5.958

6.  Gallium increases bone calcium and crystallite perfection of hydroxyapatite.

Authors:  R S Bockman; A L Boskey; N C Blumenthal; N W Alcock; R P Warrell
Journal:  Calcif Tissue Int       Date:  1986-12       Impact factor: 4.333

7.  Metabolic effects of gallium nitrate administered by prolonged infusion.

Authors:  R P Warrell; M Isaacs; C J Coonley; N W Alcock; R S Bockman
Journal:  Cancer Treat Rep       Date:  1985-06

8.  Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia.

Authors:  R P Warrell; R S Bockman; C J Coonley; M Isaacs; H Staszewski
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

9.  Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis.

Authors:  R P Warrell; A Skelos; N W Alcock; R S Bockman
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

10.  Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization.

Authors:  G Cournot-Witmer; J Zingraff; J J Plachot; F Escaig; R Lefèvre; P Boumati; A Bourdeau; M Garabédian; P Galle; R Bourdon; T Drüeke; S Balsan
Journal:  Kidney Int       Date:  1981-09       Impact factor: 10.612

View more
  8 in total

Review 1.  Modulation of bone calcium-binding sites regulates plasma calcium: an hypothesis.

Authors:  F Bronner; W D Stein
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

Review 2.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 3.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Gallium nitrate. A review of its pharmacological properties and therapeutic potential in cancer related hypercalcaemia.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

5.  Developmental toxicity evaluation of gallium nitrate in mice.

Authors:  M Gómez; D J Sánchez; J L Domingo; J Corbella
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

6.  Bone tissue incorporates in vitro gallium with a local structure similar to gallium-doped brushite.

Authors:  M Korbas; E Rokita; W Meyer-Klaucke; J Ryczek
Journal:  J Biol Inorg Chem       Date:  2003-11-29       Impact factor: 3.358

7.  Highly-Bioreactive Silica-Based Mesoporous Bioactive Glasses Enriched with Gallium(III).

Authors:  Sandra Sanchez-Salcedo; Gianluca Malavasi; Antonio J Salinas; Gigliola Lusvardi; Luca Rigamonti; Ledi Menabue; Maria Vallet-Regi
Journal:  Materials (Basel)       Date:  2018-03-02       Impact factor: 3.623

Review 8.  Gallium containing bioactive materials: A review of anticancer, antibacterial, and osteogenic properties.

Authors:  Fatih Kurtuldu; Nurshen Mutlu; Aldo R Boccaccini; Dušan Galusek
Journal:  Bioact Mater       Date:  2022-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.